Last reviewed · How we verify
BENZTROPINE MESYLATE
BENZTROPINE MESYLATE is a drug. It is currently FDA-approved (first approved 1954) for Parkinsonism, Extrapyramidal Disorders.
Benzatropine mesylate is a small molecule that acts as a muscarinic acetylcholine receptor M1 antagonist. It has been studied in clinical trials for various conditions, including schizophrenia spectrum and other psychotic disorders, back pain, sciatica, schizophrenia, and schizoaffective disorder.
At a glance
| Generic name | BENZTROPINE MESYLATE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1954 |
Approved indications
- Parkinsonism
- Extrapyramidal Disorders
Common side effects
- Urinary retention
- Toxic psychosis
- Tachycardia
- Nausea
- Nervousness
- Numbness of fingers
- Listlessness
- Loss of appetite and weight
- Hyperthermia
- Heat stroke
- Exacerbation of pre-existing psychotic symptoms
- Dry mouth
Drug interactions
- phenothiazines
- haloperidol
- tricyclic antidepressants
Key clinical trials
- Anticholinergic Deprescription in Schizophrenia (PHASE4)
- CLOZAPINE Response in Biotype-1 (PHASE4)
- Reduction of Anticholinergic Medications Among Persons With Schizophrenia or Other Psychiatric Disorders (NA)
- Patient Education and Duloxetine, Alone and in Combination, for Patients With Multisystem Functional Somatic Disorder (PHASE4)
- Bioequivalence Study of Two Oral Haloperidol Tablets Formulations in Healthy Subjects Under Fasting Conditions (PHASE1)
- Bioequivalence Study of Two Oral Haloperidol Tablets Formulations in Healthy Subjects Under Fed Conditions (PHASE1)
- A Phase II/III Double-Blind Study of Amitriptyline and Mexiletine for Painful Neuropathy in HIV Infection (PHASE2)
- Insight Enhancement Program vs. Metacognitive Training for Psychosis in Patients With Schizophrenia: A Three-Armed Comparative Randomized Controlled Trial (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BENZTROPINE MESYLATE CI brief — competitive landscape report
- BENZTROPINE MESYLATE updates RSS · CI watch RSS
Frequently asked questions about BENZTROPINE MESYLATE
What is BENZTROPINE MESYLATE?
What is BENZTROPINE MESYLATE used for?
When was BENZTROPINE MESYLATE approved?
What development phase is BENZTROPINE MESYLATE in?
What are the side effects of BENZTROPINE MESYLATE?
Related
- Indication: Drugs for Parkinsonism
- Indication: Drugs for Extrapyramidal Disorders
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing